17 recruiting. 17 Phase 1, 17 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Recruiting 17 |
| Phase 2 | 17 | Recruiting 17 |
Follow Essen Biotech: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors EBNK-001 + IL-15 + Pembrolizumab - Cancer, Sarcoma | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 83 | 2026-02-01 | 2026-02-18 |
| Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK - Cancer, Breast Cancer | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 85 | 2026-02-01 | 2026-02-18 |
| Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas CD146/HER2 CAR-T cells - Sarcoma, Sarcoma, Kaposi | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 60 | 2025-05-29 | 2025-07-15 |
| Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer GPC3 CD146 CAR-T cells - Ovarian Cancer, Ovarian Carcinoma | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 80 | 2025-04-29 | 2025-07-16 |
| Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer Mesothelin and Claudin 18.2 CAR-T cells - Pancreatic Cancer, Pancreatic Carcinoma | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 60 | 2025-04-29 | 2025-07-15 |
| Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma BCMA/GPRC5D CAR-T cells - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 60 | 2025-04-29 | 2025-06-22 |
| TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamide, Fludarabine - Brain Tumor, Brain Metastases | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 85 | 2024-10-20 | 2024-11-05 |
| Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamide, Fludarabine - Colorectal Cancer, Colon Cancer | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 85 | 2024-09-29 | 2024-11-05 |
| TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamid, Fludarabine - Stomach Cancer, Stomach Cancer Recurrent | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 75 | 2024-09-10 | 2024-11-12 |
| TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamid, Fludarabine - Breast Cancer, Breast Carcinoma | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 85 | 2024-08-22 | 2024-11-12 |
| TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamide, Fludarabine - Lung Cancer, Lung Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 85 | 2024-08-20 | 2024-10-15 |
| Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease Drug Product is administered by IV infusion following myeloablative conditioning with busulfan - Sickle Cell Disease, Sickle-Cell Disease With Crisis | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 85 | 2024-08-01 | 2024-11-05 |
| Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) CD19- BCMA CAR-T cells - Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 75 | 2024-07-10 | 2024-10-15 |
| Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells CD5/CD7 CAR-T - T Cell Lymphoma, T Cell Leukemia | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 60 | 2024-07-10 | 2024-11-12 |
| Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML CD123/CD33 CART - AML, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 85 | 2024-07-10 | 2024-11-12 |
| Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). CD19/CD22-CAR T cells - Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 75 | 2024-07-10 | 2025-08-06 |
| Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases BCMA/CD19 CAR-T cells - Autoimmune Diseases, Systemic Lupus Erythematosus | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 60 | 2024-05-29 | 2024-11-05 |
Autoimmune Diseases (3) · Breast Neoplasms (3) · Colorectal Neoplasms (3) · Glioblastoma (3) · Ovarian Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Esophageal Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Liver Neoplasms (2) · Lung Neoplasms (2) · Lupus Erythematosus, Systemic (2) · Lymphoma (2) · Lymphoma, Follicular (2) · Lymphoma, Non-Hodgkin (2) · Melanoma (2)
Cyclophosphamide (6) · Interleukin-2 (6) · fludarabine (6) · pembrolizumab (6) · Busulfan (1) · Interleukin-15 (1) · Mesothelin (1)
China (17)